FDA Adverse Event Malfunction Summary report: N

TELIGEN

MDR report key: 2042514 · Received April 6, 2011

Report

Report Number
2124215-2011-01276
Event Type
Malfunction
Date Received
April 6, 2011
Date of Event
January 18, 2011
Report Date
January 9, 2012
Manufacturer
GUIDANT CRM CLONMEL IRELAND
Product Code
LWS
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

AS NO FURTHER INFORMATION CONCERNING THIS REPORT IS EXPECTED, OUR INVESTIGATION IS COMPLETE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Additional Manufacturer Narrative · 1

ALL AVAILABLE INFORMATION INDICATES THAT THIS PRODUCT REMAINS IN SERVICE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Description of Event or Problem · 1

ADDITIONAL INFORMATION WAS PROVIDED THAT HIGH RV IMPEDANCES WERE AGAIN DETECTED BY THE REMOTE MONITORING SYSTEM. BOSTON SCIENTIFIC TECHNICAL SERVICES (TS) WAS CONSULTED AND THEY DISCUSSED THAT THE IMPEDANCE MEASUREMENTS WERE VARIABLE, BUT SENSING MEASUREMENTS WERE STABLE, AND THERE WAS NO NOISE OR OVERSENSING NOTED. TS PROVIDED OPTIONS OF BRINGING THE PATIENT IN FOR TESTING OR CONTINUE TO MONITOR. NO ADVERSE PATIENT EFFECTS WERE REPORTED.

Description of Event or Problem · 1

BOSTON SCIENTIFIC RECEIVED INFORMATION THAT THE LATITUDE SYSTEM DETECTED A RED ALERT FROM THIS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) DUE TO HIGH RIGHT VENTRICULAR (RV) PACING IMPEDANCES. THE ALERT WAS DELIVERED TO THE PATIENT'S CLINIC. NO ADVERSE PATIENT EFFECTS WERE REPORTED. ADDITIONAL INFORMATION WAS PROVIDED THAT THE DAILY IMPEDANCE MEASUREMENTS WERE REVIEWED WITH THE PATIENT'S CLINIC, AND THIS PATIENT WAS NOTED TO HAVE A HIGH, BUT WITHIN RANGE, RV IMPEDANCE. IT WAS NOTED THAT THE PATIENT WOULD CONTINUE TO BE MONITORED AT THIS TIME.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TELIGEN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR LWS GUIDANT CRM CLONMEL IRELAND E110

Patients

Seq Age Sex Outcome Treatment
1 80 YR (B)(4)| (B)(4)| (B)(4)| (B)(4)| (B)(4)